With a one year PEG ratio of 0.64, Castle Biosciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 6.04% of US stocks.
Castle Biosciences Inc's stock had its IPO on July 25, 2019, making it an older stock than just 1.67% of US equities in our set.
The price/operating cash flow metric for Castle Biosciences Inc is higher than 94.98% of stocks in our set with a positive cash flow.
Stocks that are quantitatively similar to CSTL, based on their financial statements, market capitalization, and price volatility, are AXTI, PING, MLAB, KRMD, and AYX.
Castle Biosciences, Inc. provides healthcare imaging services. The Company offers diagnostic and prognostic testing solutions for cancers, as well as research and development activities. Castle Biosciences serves customers in the United States.
CSTL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for CSTL, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Castle Biosciences Inc ranked in the 68th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Castle Biosciences Inc, consider:
As a business, CSTL is generating more cash flow than merely 15.44% of positive cash flow stocks in the Healthcare.
The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately only 7.66% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Castle Biosciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
CRHM, HCSG, LH, ABBV, and SGRY can be thought of as valuation peers to CSTL, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Castle Biosciences ([[CSTL]] -5.7%) announced preliminary performance results for 4Q20 and FY20.Delivered 18,185 gene expression profile test reports in 2020.Final, expanded LCD for CMS coverage for DecisionDx-Melanoma test became effective on Dec. 6, 2020. Since the effective date, more than 90% of Medicare beneficiaries whose clinicians order DecisionDx-Melanoma as part...